PD-1单抗Pembrolizumab治疗28例晚期肺癌的有效性及安全性观察

目的观察程序性死亡受体1(PD-1)单克隆抗体(单抗)Pembrolizumab治疗晚期肺癌的疗效和毒副反应。方法28例晚期肺癌患者,均接受PD-1单抗Pembrolizumab治疗,评价其近期疗效和毒副反应发生情况。结果28例患者中,3例患者于治疗1个月内因原发肿瘤进展、病情加重而死亡。其余25例患者,完全缓解1例、部分缓解4例、疾病稳定14例、疾病进展6例,客观反应率20.0%(5/25),疾病控制率76.0%(19/25)。可评价疗效的25例患者中位无进展生存期(PFS)为5.1个月,95%CI=(2.9,7.4)。28例患者常见的不良反应为疲乏5例(17.9%)、发热4例(14.3%)、免疫相关性肺炎6例(21.4%),其次为甲状腺功能减退3例(10.7%)、皮疹2例(7.1%)、腹泻2例(7.1%)、甲状腺功能亢进1例(3.6%)、心脏毒性1例(3.6%)。结论PD-1单抗Pembrolizumab对晚期肺癌疗效可,毒副作用可耐受。

EfficaObservation on effectiveness and safety of PD-1 monoclonal antibody Pembrolizumab in 28 patients with advanced lung cancer

Objective To observe the efficacy and toxic and side effect of programmed death 1(PD-1)monoclonal antibody Pembrolizumab in advanced lung cancer.Methods 28 patients with advanced lung cancer were treated with PD-1 monoclonal antibody pembrolizumab,and their short-term efficacy and toxic and side effects were evaluated.Results Among the 28 patients,3 cases died of primary tumor progression and aggravation within 1 month after treatment.Among the other 25 patients,there were 1 case of complete remission,4 cases of partial remission,14 cases of disease stabilization,6 cases of disease progression.The objective response rate was 20.0%(5/25),and the disease control rate was 76.0%(19/25).Median progression free survival(PFS)was 5.1 months and 95%CI=(2.9,7.4)in 25 patients.The common adverse reactions were fatigue in 5 cases(17.9%),fever in 4 cases(14.3%),immune-related pneumonia in 6 cases(21.4%),hypothyroidism in 3 cases(10.7%),rash in 2 cases(7.1%),diarrhea in 2 cases(7.1%),hyperthyroidism in 1 case(3.6%)and cardiotoxicity in 1 case(3.6%).Conclusion PD-1 monoclonal antibody Pembrolizumab shows good efficacy on advanced lung cancer,and the toxic and side effects are tolerable.